OVID THERAPEUTICS INC
OVIDNASDAQTrading Snapshot
- Day Range
- $2.49 – $2.57
- 52-Week Range
- $0.50 – $3.11
- Volume
- $1.88B
- Avg Volume
- $1.49B
- Shares Outstanding
- 186.6M
- Next Earnings
- Sep 22, 2026
Fundamentals Snapshot
- Annual Revenue
- $7M
- Last Q Revenue
- $2M
- P/E Ratio
- —
- P/S Ratio
- 65.8x
- EPS (TTM)
- $-0.24
- Dividend Yield
- —
Why Investors Own OVID
- ✓High-growth profile — revenue up +1.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 72% gross margin and 16% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About OVID THERAPEUTICS INC
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.